StockNews.AI
IDYA
StockNews.AI
29 days

IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event

1. IDYA will participate in the 2025 BTIG Virtual Biotechnology Conference. 2. CEO Yujiro Hata will discuss company developments during the fireside chat. 3. Live webcast of the event will be available on IDEAYA's website. 4. IDEAYA focuses on precision medicine and developing targeted cancer therapies. 5. The company has a robust pipeline aimed at unmet cancer treatment needs.

5m saved
Insight
Article

FAQ

Why Bullish?

Participation in investor events typically boosts investor confidence and visibility, as seen in other biotech firms successfully engaging audiences and gaining market interest.

How important is it?

The announcement signals proactive investor relations, likely fostering interest and engagement with the stock.

Why Short Term?

Immediate potential for price movement due to investor engagement at the conference, similar to recent events for biotech companies that have seen stocks rise shortly after participation.

Related Companies

REGNAMGNBMYNVTA
, /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations event. 2025 BTIG Virtual Biotechnology ConferenceTuesday, July 29th, 2025 at 4:40 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Justin Zelin, Director, Biotechnology Research Analyst A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies to address unmet medical needs in cancer. The company integrates small molecule drug discovery, structural biology and bioinformatics with extensive capabilities in identifying and validating translational biomarkers to develop potentially first-in-class targeted therapies for selected patient populations. IDEAYA has built a robust pipeline of targeted therapies focused on synthetic lethality and antibody-drug conjugates, or ADCs, including bispecifics, with the goal of improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025. Investor and Media ContactIDEAYA BiosciencesJoshua Bleharski, Ph.D.Chief Financial Officer[email protected] SOURCE IDEAYA Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News